BRITISH competition officials
have accused GlaxoSmithKline of
“market abuse” over allegations
that the company paid generic
rivals to delay the release of
their own versions of its Seroxat
(paroxetine) SSRI medication.
The UK Office of Fair Trading
says GSK made agreements which
infringed competition law with
Alpharma, Generics (UK) Limited
and Norton Healthcare Limited,
each of whom were attempting to
supply generic paroxetine products.
“In each case GSK challenged the
generic companies with allegations
that their products would infringe
GSK’s patents,” and each of the
generic suppliers subsequently
made an agreement with GSK to
resolve the legal action.
“The OFT’s provisional view is
that these agreements included
substantial payments from GSK to
the generic companies in return for
their commitment to delay their
plans to supply paroxetine,” an OfT
statement said.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Apr 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.